A gel containing recombinant collagen for inhibiting the growth of skin scars and a preparation method thereof

Abstract

The application discloses a gel containing recombinant collagen for inhibiting growth of skin scars and a preparation method thereof. The preparation method comprises the following steps: S1, dissolving trimethylsiloxy silicate in low-viscosity polydimethylsiloxane, stirring until uniform dissolution, and preparing solution A; S2, dissolving recombinant collagen in purified water, stirring until uniform dissolution, and preparing solution B; S3, adding fumed silica and high-viscosity polydimethylsiloxane into a stirring tank, slowly adding the solution A prepared in the step S1 and the solution B prepared in the step S2 into the stirring tank, and stirring under the condition of 20-35 DEG C until uniform mixing, so that the gel is obtained. The gel can effectively reduce, soften and improve the appearance of scars, inhibit the proliferation of scars, relieve the itching of scars, and also has a good improvement effect on the skin, and can effectively avoid the occurrence of allergic reactions.

Description

Technical Field

[0001] This invention belongs to the field of medical product preparation technology, specifically relating to a gel containing recombinant collagen that inhibits skin scar growth and its preparation method. Background Technology

[0002] Hypertrophic scars are an inevitable product of the wound healing process. They refer to the changes in the external morphology and histopathology of skin tissue that occur during the repair process after a patient has suffered an injury. In clinical wound treatment, scars of varying degrees can form in any organ and tissue. These scars may cause local itching, pain, and contractures, severely affecting the patient's function and appearance, having a serious impact on the patient's physical and mental health, and even increasing the burden on the patient's family.

[0003] Scars located on the skin surface affect appearance and are difficult to treat. Although there are many clinical treatment options for scars, the overall efficacy is limited and there are disadvantages such as large side effects and high costs. In contrast, topical scar gel preparations are non-invasive, painless, and easy to use compared to clinical treatment options. They have the advantages of being safe and effective in inhibiting the growth of scars on the skin surface.

[0004] Recombinant human collagen has a strong affinity for protein molecules on the skin surface and exhibits resistance, biodegradability, and biocompatibility. Because recombinant human collagen is structurally similar to human skin collagen, it has good compatibility and can rapidly diffuse into the deep layers of the skin. Furthermore, the outer surface of the recombinant collagen molecule contains numerous carboxyl and hydroxyl groups, as well as abundant natural moisturizing factors such as glycine, which can enhance the water retention capacity of tissue cells, thus moisturizing the skin and effectively improving itching caused by dry skin in patients with scars.

[0005] Currently, domestic and international methods for inhibiting scar growth mainly employ local drug injections, skin grafts, surgical excision and skin grafting, compression therapy, and dermabrasion. However, these treatments are not yet fully mature in clinical practice, and their efficacy remains to be observed. Furthermore, some require long treatment times, are painful, prone to recurrence, and can lead to adverse consequences, making many methods unsatisfactory. Scar gel application is suitable for healed scars (hypertrophic scars and keloids) left on any part of the body due to surgery, car accidents, cuts, or burns. It provides a physical barrier between the scar and the external environment, keeping the scar moist and clean, thus helping to improve the overall condition of the scar, reducing its size and lightening its color, achieving a therapeutic effect. It can also be used in conjunction with other scar treatment methods to enhance the therapeutic effect.

[0006] In view of this, the present invention is proposed. Summary of the Invention

[0007] To address the aforementioned technical problems, one of the objectives of this invention is to provide a gel containing recombinant collagen that inhibits scar growth. This gel can effectively reduce and soften scars and improve their appearance, inhibit scar hyperplasia, relieve scar itching, and also improve the skin, effectively preventing allergic reactions.

[0008] Another object of the present invention is to provide a method for preparing the gel containing recombinant collagen that inhibits scar growth.

[0009] To achieve the above objectives, the present invention adopts the following technical solution:

[0010] In a first aspect, the present invention provides a method for preparing a gel containing recombinant collagen that inhibits the growth of skin scars, comprising the following steps:

[0011] S1. Dissolve trimethylsiloxysilicate in low-viscosity polydimethylsiloxane and stir until homogeneous to prepare solution A;

[0012] S2. Dissolve the recombinant collagen in purified water and stir until it is evenly dissolved to prepare solution B;

[0013] S3. Add fumed silica and high-viscosity polydimethylsiloxane to a mixing tank, then slowly add solution A prepared in step S1 and solution B prepared in step S2 to the mixing tank. Stir at 20-35°C until the mixture is homogeneous to obtain the gel.

[0014] In the above technical solution, the resulting gel contains polydimethylsiloxanes of different viscosities. First, trimethylsiloxysilicate is fully dissolved and dispersed using polydimethylsiloxane with a preferred lower viscosity and dosage range. Then, polydimethylsiloxane with a preferred higher viscosity and dosage range is used to cover the scar surface, providing a physical barrier between the scar and the external environment, keeping the scar moist and clean. Specifically, the purpose of step S1 is to dissolve the solid trimethylsiloxysilicate in low-viscosity polydimethylsiloxane to prevent direct addition of solid trimethylsiloxysilicate to the complex, which would hinder dispersion, affect the cross-linking reaction, and consequently affect the gel formation effect in step S3. The purpose of S1 and S2 is to ensure thorough and uniform mixing of the components while eliminating air bubbles to ensure the gel formation effect in S3. The scar gel formed in S3 can be directly adhered to the wound surface during use without external fixation.

[0015] In the above technical solution, the fumed silica is silylated silica. The fumed silica of the present invention can be more uniformly dispersed in the scar gel within the preferred particle size range and preferred dosage range, forming a microporous structure in the scar gel, which is beneficial to increase the air permeability of the gel, can ensure the normal breathing function of the skin, and also has a certain antibacterial effect.

[0016] In the above technical solution, trimethylsiloxysilicate is a film-forming agent, belonging to MQ resin, which has good film strength. Within the preferred dosage range, it can effectively improve the waterproof, oil-repellent and migration-resistant properties of the product.

[0017] In the above technical solution, the recombinant collagen gel is constructed and industrially expressed using Pichia pastoris genetically engineered bacteria, and is free of endotoxins. The recombinant collagen possesses excellent hydrophilicity and stability, and its structure is 100% identical to the corresponding portion of the natural collagen gene sequence, ensuring it will not cause immune rejection when applied to the human body. After applying recombinant collagen to superficial wounds, scab formation is advanced by 1-2 days, shortening wound healing time. Naturally scarred skin may leave unevenness and pigmentation; after using recombinant collagen, the wound becomes smoother and more even, improving wound healing quality and eliminating obvious scarring. The overall size and depth of the wound are significantly improved. The recombinant collagen of this invention, as a superficial wound repair material, is suitable for use in biomedical materials, cosmetics, and other fields.

[0018] Preferably, the amounts of each substance, by weight, are as follows:

[0019]

[0020] More preferably, the amounts of each substance, by weight, are as follows:

[0021]

[0022] Preferably, in step S1, the viscosity of the low-viscosity polydimethylsiloxane is 50-200 cSt; and the stirring time is 0.5-1 h.

[0023] More preferably, in step S1, the viscosity of the low-viscosity polydimethylsiloxane is 100-150 cSt.

[0024] Preferably, the stirring time in step S2 is 0.2h to 0.5h.

[0025] Preferably, in step S3, the viscosity of the high-viscosity polydimethylsiloxane is 10,000 to 15,000 cSt; and the particle size of the fumed silica is 5 to 15 nm.

[0026] More preferably, in step S3, the viscosity of the high-viscosity polydimethylsiloxane is 12000-13000 cSt.

[0027] Preferably, the stirring time in step S3 is 2 to 3 hours.

[0028] Secondly, the present invention also provides and claims protection for gels prepared by the above method.

[0029] Compared with the prior art, the present invention has the following beneficial effects:

[0030] (1) The present invention provides a gel containing recombinant collagen to inhibit the growth of skin scars. When applied to the healed wound, as the moisture evaporates, the film-forming matrix cross-links with each other and gradually forms a protective membrane. The resin surface contains cations, which can form an electrostatic force with the cell surface and adhere tightly to the healed wound, making the application area non-greasy and less likely to stick to clothing.

[0031] (2) In the preparation process of this invention, specific amounts of high-viscosity polydimethylsiloxane and low-viscosity polydimethylsiloxane are used. Specifically, trimethylsiloxysilicate is first fully dissolved and dispersed with low-viscosity polydimethylsiloxane, and then polydimethylsiloxane with a preferred higher viscosity and dosage range is used to cover the scar surface. At the same time, a certain comparative test was conducted on the viscosity range and the dosage range of the two. By introducing two polydimethylsiloxanes with different viscosities and accurately controlling the dosage of each raw material, the resulting scar removal gel has good stability and no oil seepage or phase separation. It has a good feel when applied. After being applied to the skin, it can quickly form a film. The water vapor permeability is significantly lower, which can effectively prevent water loss in the scar area, inhibit the large-scale production of fibroblasts and collagen, and at the same time facilitate hydration, promoting the scar to become lighter, softer and flatter.

[0032] (3) The present invention provides a method for preparing a gel containing recombinant collagen that inhibits the growth of skin scars. The preparation method is simple and efficient, and the product obtained has high stability and is suitable for industrial production applications.

[0033] In summary, the gel preparation method provided by this invention creatively proposes to use polydimethylsiloxanes of different viscosities to treat materials during the preparation process, and obtains an optimal range of usage through systematic optimization; the prepared gel has a good feel and excellent scar removal effect. Attached Figure Description

[0034] Figure 1 Images of cells from in vitro cytotoxicity tests; column A shows the cell distribution in Example 1, column B shows the cell distribution in Example 2, and column C shows the cell distribution in Example 3. Detailed Implementation

[0035] The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.

[0036] It should be noted that some material information in the embodiments of the present invention is as follows:

[0037] The recombinant collagen used in this invention was purchased from Jiangsu Jiangshan Juyuan Biotechnology Co., Ltd.

[0038] The trimethylsilyloxysilicate used in this invention was purchased from DuPont.

[0039] The polydimethylsiloxane used in this invention was purchased from DuPont.

[0040] The fumed silica used in this invention was purchased from Dow Corning.

[0041] Example 1

[0042] A gel containing recombinant collagen to inhibit skin scar growth comprises, by weight, the following raw materials (see Table 1), wherein the high-viscosity polydimethylsiloxane has a viscosity of 12500 cSt, and the low-viscosity polydimethylsiloxane has a viscosity of 100 cSt:

[0043] Table 1. Raw material composition in Example 1

[0044]

[0045] This embodiment also provides a method for preparing the above-mentioned gel, comprising the following steps:

[0046] (1) Dissolve trimethylsiloxysilicate in low-viscosity polydimethylsiloxane and stir for 0.5 h until it is uniformly dissolved to prepare solution A;

[0047] (2) Dissolve the recombinant collagen in purified water and stir for 1 hour until it is evenly dissolved to prepare solution B;

[0048] (3) Add fumed silica and high-viscosity polydimethylsiloxane to a stirring tank, then slowly add solution A and solution B to the stirring tank. Stir for 2 hours at a temperature of 30°C until the mixture is homogeneous, and then prepare the gel.

[0049] Example 2

[0050] A gel containing recombinant collagen to inhibit skin scar growth comprises, by weight, the following raw materials (see Table 2), wherein the high-viscosity polydimethylsiloxane has a viscosity of 12500 cSt, and the low-viscosity polydimethylsiloxane has a viscosity of 100 cSt:

[0051] Table 2. Raw material composition in Example 2

[0052]

[0053] This embodiment also provides a method for preparing the above-mentioned gel, comprising the following steps:

[0054] (1) Dissolve trimethylsiloxysilicate in low-viscosity polydimethylsiloxane and stir for 0.5 h until it is uniformly dissolved to prepare solution A;

[0055] (2) Dissolve the recombinant collagen in purified water and stir for 1 hour until it is evenly dissolved to prepare solution B;

[0056] (3) Add fumed silica and high-viscosity polydimethylsiloxane to a stirring tank, then slowly add solution A and solution B to the stirring tank. Stir for 2 hours at a temperature of 30°C until the mixture is homogeneous, and then prepare the gel.

[0057] Example 3

[0058] A gel containing recombinant collagen to inhibit skin scar growth comprises, by weight, the following raw materials (see Table 3), wherein the high-viscosity polydimethylsiloxane has a viscosity of 12500 cSt, and the low-viscosity polydimethylsiloxane has a viscosity of 100 cSt:

[0059] Table 3. Raw material composition in Example 3

[0060]

[0061]

[0062] This embodiment also provides a method for preparing the above-mentioned gel, comprising the following steps:

[0063] (1) Dissolve trimethylsiloxysilicate in low-viscosity polydimethylsiloxane and stir for 0.5 h until it is uniformly dissolved to prepare solution A;

[0064] (2) Dissolve the recombinant collagen in purified water and stir for 1 hour until it is evenly dissolved to prepare solution B;

[0065] (3) Add fumed silica and high-viscosity polydimethylsiloxane to a stirring tank, then slowly add solution A and solution B to the stirring tank. Stir for 2 hours at a temperature of 30°C until the mixture is homogeneous, and then prepare the gel.

[0066] Comparative Example 1

[0067] A gel containing recombinant collagen to inhibit skin scar growth, made by weight of the following raw materials (see Table 4), wherein the viscosity of the polydimethylsiloxane is 12500 cSt:

[0068] Table 4. Raw material composition in Comparative Example 1

[0069]

[0070] This comparative example also provides a method for preparing the above-mentioned gel, comprising the following steps:

[0071] (1) Dissolve recombinant collagen in purified water and stir for 1 hour until it is evenly dissolved to prepare solution A;

[0072] (2) Trimethylsiloxane, fumed silica and polydimethylsiloxane were added to a mixing tank, and then solution A was slowly added to the mixing tank. The mixture was stirred for 2 hours at 30°C until it was homogeneous, and the gel was prepared.

[0073] Comparative Example 2

[0074] A gel containing recombinant collagen to inhibit skin scar growth comprises, by weight, the following raw materials (see Table 5), wherein the high-viscosity polydimethylsiloxane has a viscosity of 12500 cSt, and the low-viscosity polydimethylsiloxane has a viscosity of 350 cSt:

[0075] Table 5. Raw material composition in Comparative Example 2

[0076]

[0077] This comparative example also provides a method for preparing the above-mentioned gel, comprising the following steps:

[0078] (1) Dissolve trimethylsiloxysilicate in low-viscosity polydimethylsiloxane and stir for 0.5 h until it is uniformly dissolved to prepare solution A;

[0079] (2) Dissolve the recombinant collagen in purified water and stir for 1 hour until it is evenly dissolved to prepare solution B;

[0080] (3) Add fumed silica and high-viscosity polydimethylsiloxane to a stirring tank, then slowly add solution A and solution B to the stirring tank. Stir for 2 hours at a temperature of 30°C until the mixture is homogeneous, and then prepare the gel.

[0081] Comparative Example 3

[0082] A gel containing recombinant collagen to inhibit skin scar growth comprises, by weight, the following raw materials (see Table 6), wherein the high-viscosity polydimethylsiloxane has a viscosity of 12500 cSt, and the low-viscosity polydimethylsiloxane has a viscosity of 100 cSt:

[0083] Table 6. Raw material composition in Comparative Example 3

[0084]

[0085] This comparative example also provides a method for preparing the above-mentioned gel, comprising the following steps:

[0086] (1) Dissolve trimethylsiloxysilicate in low-viscosity polydimethylsiloxane and stir for 0.5 h until it is uniformly dissolved to prepare solution A;

[0087] (2) Dissolve the recombinant collagen in purified water and stir for 1 hour until it is evenly dissolved to prepare solution B;

[0088] (3) Add fumed silica and high-viscosity polydimethylsiloxane to a stirring tank, then slowly add solution A and solution B to the stirring tank. Stir for 2 hours at a temperature of 30°C until the mixture is homogeneous, and then prepare the gel.

[0089] Experimental Example 1

[0090] The gels prepared in Examples 1-3 and Comparative Examples 1-3 were evaluated for their feel, film-forming properties, and storage stability. The evaluation results are shown in Table 7.

[0091] Table 7 Physical properties of the gels prepared in the examples and comparative examples

[0092] Example 1 It has a smooth texture and is easy to apply. better No phase separation, no oil production Example 2 It has a smooth texture and is easy to apply. better No phase separation, no oil production Example 3 It has a smooth texture and is easy to apply. better No phase separation, no oil production Comparative Example 1 It has a rough texture and a large grainy feel. Poor There is phase separation and oil production. Comparative Example 2 It feels slightly rough, with a fine grainy texture. Slightly worse No phase separation, oil production Comparative Example 3 It feels slightly rough, with a fine grainy texture. Slightly worse No phase separation, oil production

[0093] Comparative Example 1, lacking the addition of low-viscosity polydimethylsiloxane, resulted in poor product dispersion, affecting the crosslinking reaction and leading to a rough texture, poor film-forming properties, and poor storage stability. In Comparative Example 2, the viscosity of the low-viscosity polydimethylsiloxane was too high, resulting in a slightly poorer product texture. In Comparative Example 3, the amount of low-viscosity polydimethylsiloxane was reduced, resulting in a slightly rougher product texture, poorer film-forming properties, and poorer product stability.

[0094] Experimental Example 2

[0095] The gels prepared in Examples 1-3 were tested for in vitro cytotoxicity according to the MTT cytotoxicity test in Appendix C of the standard GB16886.5-2017 Medical Device Biological Evaluation Part 5: In Vitro Cytotoxicity Tests.

[0096] Specifically, an enzyme-linked immunosorbent assay (ELISA) reader was used to measure the absorbance of each well at OD 490 nm and OD 570 nm. Within a certain range, the measured absorbance value was positively correlated with the cell number. Therefore, the cell viability formula can be expressed as:

[0097]

[0098] If the survival rate decreases to less than 70% of the blank, it has potential cytotoxicity. The survival rate of the test sample extract should be at least the same as or higher than that of the 100% extract; otherwise, the test should be repeated. The in vitro cytotoxicity test results of the compositions prepared in the examples are shown in [reference needed]. Figure 1 And Table 8.

[0099] Table 8 Results of in vitro cytotoxicity tests of the products in the examples.

[0100] Example 1 96.82 Non-cytotoxic Example 2 97.65 Non-cytotoxic Example 3 98.43 Non-cytotoxic

[0101] As can be seen from Table 2, Examples 1 to 3 all showed no cytotoxicity, and the formulations were safe and controllable.

[0102] Experimental Example 3

[0103] The gels prepared in Examples 1-3 and Comparative Examples 1-3 were evaluated for their human efficacy. The experimental procedures are as follows:

[0104] Trial objective: Under normal conditions, by having adult subjects use the product continuously for 56 days according to the instructions, to evaluate whether the product has an effect on improving scars.

[0105] Inclusion criteria for participants: healthy adults aged 18-55 years; visible scars (accidental injury or postoperative time no more than 1 year); no obvious skin damage, hair loss, etc. at the test site; able to cooperate well with the assessment according to the assessment protocol and maintain a regular lifestyle during the study period.

[0106] Number of subjects and usage: Sixty subjects were randomly divided into 6 groups of 10 each. Each group used the samples prepared in Examples 1-3 and Comparative Examples 1-3 respectively. Each group used the same sample twice a day for 56 consecutive days.

[0107] (1) Dermatologist assessment

[0108] ①Scar color

[0109] Dermatologists scored the color of skin scars on subjects before product use (D0), 28 days after product use (D28), and 56 days after product use (D56). Rating criteria: 0-5 points (0 points: scar color is similar to the color of adjacent normal skin; 1 point: slightly pink; 3 points: mixed color; 5 points: darker color).

[0110] ② Scar softness

[0111] Dermatologists scored the softness of skin scars on subjects before product use (D0), 28 days after product use (D28), and 56 days after product use (D56). The rating criteria were 0-5 points (0 points: normal; 1 point: soft (skin can deform with minimal resistance); 2 points: flexible and malleable (can deform under pressure); 3 points: hard (no elasticity when pressed, feels lumpy); 4 points: cord-like tissue; 5 points: contracture deformity (permanent shortening leading to functional impairment)).

[0112] ③ Height of scar protrusion

[0113] Dermatologists scored the height of raised scars on subjects' skin before product use (D0), 28 days after product use (D28), and 56 days after product use (D56). The rating criteria were 0-5 points (0 for "flat scar", 1 for "less than 1 mm", 2 for "1-2 mm", 3 for "2-3 mm", 4 for "3-4 mm", and 5 for "more than 4 mm").

[0114] ④ Itching of scars

[0115] Dermatologists scored the degree of itching on skin scars in subjects before product use (D0), 28 days after product use (D28), and 56 days after product use (D56). The rating criteria were 0-5 points (0 for "no itching symptoms", 1 for "occasional mild itching", 2 for "intermittent mild itching", 3 for "intermittent moderate itching", 4 for "intermittent severe itching", and 5 for "persistent severe itching").

[0116] ⑤ Scar pain

[0117] Dermatologists scored the degree of itching of skin scars on subjects before product use (D0), after 28 days of product use (D28), and after 56 days of product use (D56). The rating criteria were 0-5 points (0 for "no pain symptoms", 1 for "mild pain upon pressure", 2 for "occasional mild pain", 3 for "intermittent mild pain", 4 for "intermittent moderate pain", and 5 for "persistent severe pain").

[0118] The total score for scar severity is obtained by adding up the scores of the five indicators mentioned above. A total score of 0 is normal, 1-5 is mild, 6-14 is moderate, and 15-25 is severe.

[0119] The overall evaluation criteria for scar improvement are as follows:

[0120] The efficacy index is calculated as (total score before treatment - total score after treatment) / total score before treatment * 100%. The evaluation is based on four criteria: basic cure, significant effect, basic effectiveness, and ineffectiveness.

[0121] Basic cure: efficacy index ≥ 90%; Significant effect: efficacy index 70%-89%; Basically effective: efficacy index 30%-69%; Ineffective: efficacy index < 30%. The effectiveness rate is calculated as basic cure + significant effect + basically effective. The treatment results are shown in Table 9.

[0122] Table 9. Dermatologists' assessment of scar improvement results

[0123] Example 1 4 5 1 0 100％ Example 2 3 5 2 0 100％ Example 3 2 7 1 0 100％ Comparative Example 1 0 5 3 2 80％ Comparative Example 2 0 6 3 1 90％ Comparative Example 3 0 5 4 1 90％

[0124] (2) Subject self-assessment

[0125] The scar condition was observed and recorded statistically by group follow-up visits. The efficacy of the trial results was divided into three levels, based on the comparison of photos taken before and after the use under the same conditions: Basically cured: scar pigmentation and protrusion have disappeared visibly; Significantly effective: scar pigmentation and protrusion have significantly faded visibly (significant improvement); Basically effective: scar pigmentation and protrusion have slightly faded (improvement but not significant); Ineffective: scar pigmentation and protrusion have essentially remained unchanged (no effect). The total effective rate was calculated as basically cured + significantly effective + basically effective, and the results are shown in Table 10. Furthermore, the subjects reported no adverse reactions after using the above products.

[0126] Table 10. Subjects' self-assessment of scar improvement results

[0127] Example 1 2 7 1 0 100％ Example 2 1 6 3 0 100％ Example 3 1 7 2 0 100％ Comparative Example 1 0 4 4 2 80％ Comparative Example 2 0 5 4 1 90％ Comparative Example 3 0 6 3 1 90％

[0128] Based on the evaluation results of the dermatologists and subjects mentioned above, the recombinant collagen-containing gel for inhibiting scar growth of the present invention has a good scar-fading effect and is non-toxic. When applied to a healed wound, as moisture evaporates, the film-forming matrix cross-links with each other, gradually forming a protective membrane. The resin surface contains cations, which can form electrostatic interactions with the cell surface, adhering tightly to the healed wound, making the application area non-greasy and less likely to stick to clothing. The silicone gel component within the protective membrane inhibits the evaporation of moisture from the healed tissue, and through hydration, coordinates the secretion and arrangement of collagen in the healed wound tissue, achieving a better effect in inhibiting scar growth.

[0129] The applicant declares that the technical solution of this invention is illustrated through the above embodiments, but this invention is not limited to the above embodiments, that is, it does not mean that this invention must rely on the above embodiments to be implemented. Those skilled in the art should understand that any improvements to this invention, equivalent substitutions of individual raw materials in the product of this invention, additions of auxiliary components, and selection of specific methods, all fall within the protection scope and disclosure scope of this invention.

Claims

1. A method for preparing a gel containing recombinant collagen that inhibits skin scar growth, characterized in that, Includes the following steps: S1. Dissolve trimethylsiloxysilicate in low-viscosity polydimethylsiloxane and stir until homogeneous to prepare solution A; S2. Dissolve the recombinant collagen in purified water and stir until it is evenly dissolved to prepare solution B; S3. Add fumed silica and high-viscosity polydimethylsiloxane to a mixing tank, then slowly add solution A prepared in step S1 and solution B prepared in step S2 to the mixing tank. Stir at 20-35°C until the mixture is homogeneous to obtain the gel. The amounts of each substance, by weight, are as follows: ； In step S1, the viscosity of the low-viscosity polydimethylsiloxane is 100-150 cSt; the stirring time is 0.5-1 h. In step S3, the viscosity of the high-viscosity polydimethylsiloxane is 12000-13000 cSt; and the particle size of the fumed silica is 5-15 nm.

2. The method for preparing a gel containing recombinant collagen to inhibit skin scar growth according to claim 1, characterized in that, The stirring time in step S2 is 0.2h to 0.5h.

3. The method for preparing a gel containing recombinant collagen to inhibit skin scar growth according to claim 1, characterized in that, The stirring time in step S3 is 2 to 3 hours.

4. A gel containing recombinant collagen that inhibits skin scar growth, characterized in that, It is prepared by the method described in any one of claims 1 to 3.

Images